Literature DB >> 18724774

The guinea pig as a model of infectious diseases.

Danielle J Padilla-Carlin1, David N McMurray, Anthony J Hickey.   

Abstract

The words 'guinea pig' are synonymous with scientific experimentation, but much less is known about this species than many other laboratory animals. This animal model has been used for approximately 200 y and was the first to be used in the study of infectious diseases such as tuberculosis and diphtheria. Today the guinea pig is used as a model for a number of infectious bacterial diseases, including pulmonary, sexually transmitted, ocular and aural, gastrointestinal, and other infections that threaten the lives of humans. Most studies on the immune response to these diseases, with potential therapies and vaccines, have been conducted in animal models (for example, mouse) that may have less similarity to humans because of the large number of immunologic reagents available for these other species. This review presents some of the diseases for which the guinea pig is regarded as the premier model to study infections because of its similarity to humans with regard to symptoms and immune response. Furthermore, for diseases in which guinea pigs share parallel pathogenesis of disease with humans, they are potentially the best animal model for designing treatments and vaccines. Future studies of immune regulation of these diseases, novel therapies, and preventative measures require the development of new immunologic reagents designed specifically for the guinea pig.

Entities:  

Mesh:

Year:  2008        PMID: 18724774      PMCID: PMC2706043     

Source DB:  PubMed          Journal:  Comp Med        ISSN: 1532-0820            Impact factor:   0.982


  324 in total

1.  Identification and cloning of genes associated with the guinea pig skin delayed-type hypersensitivity reaction.

Authors:  D Yang; K Nakada-Tsukui; M Ohtani; R Goto; T Yoshimura; Y Kobayashi; N Watanabe
Journal:  J Biochem       Date:  2001-04       Impact factor: 3.387

Review 2.  Surface protein adhesins of Staphylococcus aureus.

Authors:  T J Foster; M Höök
Journal:  Trends Microbiol       Date:  1998-12       Impact factor: 17.079

3.  Design and optimization of a recombinant system for large-scale production of the MPT64 antigen from Mycobacterium tuberculosis.

Authors:  Brian V Geisbrecht; Boris Nikonenko; Rowena Samala; Reiko Nakamura; Carol A Nacy; Katherine A Sacksteder
Journal:  Protein Expr Purif       Date:  2005-09-16       Impact factor: 1.650

4.  Conservation of a CD1 multigene family in the guinea pig.

Authors:  C C Dascher; K Hiromatsu; J W Naylor; P P Brauer; K A Brown; J R Storey; S M Behar; E S Kawasaki; S A Porcelli; M B Brenner; K P LeClair
Journal:  J Immunol       Date:  1999-11-15       Impact factor: 5.422

5.  Biofilm formation, icaADBC transcription, and polysaccharide intercellular adhesin synthesis by staphylococci in a device-related infection model.

Authors:  Ursula Fluckiger; Martina Ulrich; Andrea Steinhuber; Gerd Döring; Dietrich Mack; Regine Landmann; Christiane Goerke; Christiane Wolz
Journal:  Infect Immun       Date:  2005-03       Impact factor: 3.441

6.  Bacterial counts in experimental, contaminated crush wounds irrigated with various concentrations of cefazolin and penicillin.

Authors:  R Lammers; C Henry; J Howell
Journal:  Am J Emerg Med       Date:  2001-01       Impact factor: 2.469

7.  Immunity to reinfection and immunization of male guinea pigs against urethral infection with the agent of guinea pig inclusion conjunctivitis.

Authors:  T L Patterson; R G Rank
Journal:  Sex Transm Dis       Date:  1996 Mar-Apr       Impact factor: 2.830

8.  Experimental chlamydial salpingitis in immunosuppressed guinea pigs infected in the genital tract with the agent of guinea pig inclusion conjunctivitis.

Authors:  H J White; R G Rank; B L Soloff; A L Barron
Journal:  Infect Immun       Date:  1979-11       Impact factor: 3.441

9.  A new assay system for guinea pig interferon biological activity.

Authors:  Toshiko Yamamoto; Amminikutty Jeevan; Kazue Ohishi; Yasuhiro Nojima; Kiyoko Umemori; Saburo Yamamoto; David N McMurray
Journal:  J Interferon Cytokine Res       Date:  2002-07       Impact factor: 2.607

10.  Specific immune response genes of the guinea pig. I. Dominant genetic control of immune responsiveness to copolymers of L-glutamic acid and L-alanine and L-glutamic acid and L-tyrosine.

Authors:  H G Bluestein; I Green; B Benacerraf
Journal:  J Exp Med       Date:  1971-08-01       Impact factor: 14.307

View more
  86 in total

1.  Humanized Mice--A Neoteric Animal Disease Model for Ebola Virus?

Authors:  Joseph Prescott; Heinz Feldmann
Journal:  J Infect Dis       Date:  2015-11-17       Impact factor: 5.226

2.  CHO expressed recombinant human lactoferrin as an adjuvant for BCG.

Authors:  Shen-An Hwang; Marian L Kruzel; Jeffrey K Actor
Journal:  Int J Immunopathol Pharmacol       Date:  2015-08-27       Impact factor: 3.219

3.  Blood profiles in unanesthetized and anesthetized guinea pigs (Cavia porcellus).

Authors:  Wendy R Williams; Matthew S Johnston; Sarah Higgins; Angelo A Izzo; Lon V Kendall
Journal:  Lab Anim (NY)       Date:  2016-01       Impact factor: 12.625

4.  A novel recombinant human lactoferrin augments the BCG vaccine and protects alveolar integrity upon infection with Mycobacterium tuberculosis in mice.

Authors:  Shen-An Hwang; Katarzyna Wilk; Marian L Kruzel; Jeffrey K Actor
Journal:  Vaccine       Date:  2009-04-05       Impact factor: 3.641

5.  Inhaled Pyrazinoic Acid Esters for the Treatment of Tuberculosis.

Authors:  E F Young; E Perkowski; S Malik; J D Hayden; P G Durham; L Zhong; J T Welch; Miriam S Braunstein; Anthony J Hickey
Journal:  Pharm Res       Date:  2016-06-28       Impact factor: 4.200

6.  Development of a novel, guinea pig-specific IFN-γ ELISPOT assay and characterization of guinea pig cytomegalovirus GP83-specific cellular immune responses following immunization with a modified vaccinia virus Ankara (MVA)-vectored GP83 vaccine.

Authors:  Peter A Gillis; Nelmary Hernandez-Alvarado; Josephine S Gnanandarajah; Felix Wussow; Don J Diamond; Mark R Schleiss
Journal:  Vaccine       Date:  2014-05-20       Impact factor: 3.641

Review 7.  Cytomegalovirus antivirals and development of improved animal models.

Authors:  Alistair McGregor; K Yeon Choi
Journal:  Expert Opin Drug Metab Toxicol       Date:  2011-09-01       Impact factor: 4.481

Review 8.  A critical review of the in vitro and in vivo models for the evaluation of anti-infective meshes.

Authors:  O Guillaume; B Pérez Kohler; R Fortelny; H Redl; F Moriarty; R G Richards; D Eglin; A Petter Puchner
Journal:  Hernia       Date:  2018-08-28       Impact factor: 4.739

Review 9.  The non-human primate model of tuberculosis.

Authors:  D Kaushal; S Mehra; P J Didier; A A Lackner
Journal:  J Med Primatol       Date:  2012-03-20       Impact factor: 0.667

10.  Differential virulence and disease progression following Mycobacterium tuberculosis complex infection of the common marmoset (Callithrix jacchus).

Authors:  Laura E Via; Danielle M Weiner; Daniel Schimel; Philana Ling Lin; Emmanuel Dayao; Sarah L Tankersley; Ying Cai; M Teresa Coleman; Jaime Tomko; Praveen Paripati; Marlene Orandle; Robin J Kastenmayer; Michael Tartakovsky; Alexander Rosenthal; Damien Portevin; Seok Yong Eum; Saher Lahouar; Sebastien Gagneux; Douglas B Young; Joanne L Flynn; Clifton E Barry
Journal:  Infect Immun       Date:  2013-05-28       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.